Raise Your Muscle Mass And Reduce Your Type 2 Diabetes Risk

Building muscle can lower your insulin resistance risk, which in turn lowers your chances of developing pre-diabetes, and ultimately protecting you from ever suffering from diabetes type 2, researchers from the University of California in Los Angeles revealed in the Journal of Clinical Endocrinology & Metabolism. Insulin resistance is a major precursor for diabetes type...

Kidney Cells Could be Reprogrammed to Fight Disease

WASHINGTON—New research has shown that kidney cells can be gathered and reprogrammed to help treat kidney disease, according to studies published in the July issue of the Journal of the American Society of Nephrology (JASN). ...

Baxter to Invest in Early-Stage Therapies

DEERFIELD, Ill.—Baxter International Inc. has created Baxter Ventures to invest up to $200 million in equity in promising early-stage companies developing therapies that complement Baxter’s existing portfolio. ...

Mid-Atlantic Renal Coalition Launches New Website

RICHMOND, Va.—The Mid-Atlantic Renal Coalition (MARC) has launched a new website that includes an updated look and streamlined format. ...

Culturally Tailored Diabetes Program Provides Some Benefits For Asian Americans

SAN DIEGO - A culturally tailored diabetes program can help Asian Americans with type 2 diabetes achieve glycemic control that is comparable to that observed in white patients, researchers reported at the 71st Scientific Sessions of the American Diabetes Association...

Cetero fires back at scathing FDA accusations

A little more than a day after the FDA issued a scathing report on the CRO Cetero, claiming that employees at its Houston lab had routinely falsified trial data, the clinical research organization issued a release in its own defense, claiming that it had proactively contacted the FDA about a problem limited to a few lab workers who had been seeking added pay for overtime work. According to Cetero, the company contacted the FDA after it conducted an internal investigation of its own...

Horizon Pharma goes public at $9

Horizon Pharma ($HZNP) went public this morning, pricing 5.5 million shares at $9 a share. That's a little below the $10 to $12 range that it had hoped for, but not too bad considering some of the biotech IPOs that have floated at far bigger discounts so far this year. Horizon has also granted the underwriters a 30-day option to purchase up to an additional 825,000 shares at the initial public offering price to cover overallotments....

Baxter sets up $200M venture arm for early-stage investments

Baxter International is setting up its own corporate venture unit with plans to inject up to $200 million to be invested in early-stage companies with promising new technologies. "Baxter's mission is to apply innovative science to develop therapies and medical technologies that save and sustain patients' lives," said Baxter CEO Robert L. Parkinson, Jr. "As the company's internal capabilities have advanced our late-stage pipeline, we have the capacity to further accelerate the early-stage...

GSK chief sees big shakeout following R&D showdown

GlaxoSmithKline CEO Andrew Witty believes that the pharma industry is at a turning point. For the first time ever overall R&D spending in the industry is going down as development strategies undergo a top-to-bottom reevaluation. And only a handful of companies will survive the process. "There is tremendous opportunity for the few companies who solve the R&D equation," Witty told reporters, according to a report in the Philadelphia Inquirer. "It's the companies who deliver multiple new...

Flush with cash, U.K. biotech preps new discovery effort in Oxford

Armed with a fresh injection of $26 million, the U.K.'s e-Therapeutics is expanding and re-launching its discovery unit in Oxford, back where much of its original scientific inspiration came from in the early ‘90s. Altogether about 10 researchers will be brought in, either recruited or relocated, to focus on four new programs slated for human trials beginning next year. "What we have learned is that we need quality people and there are three places in the world that specialize in our...